Evogene (EVGN) vs. Arcadia Biosciences (RKDA) Head-To-Head Survey

Evogene (NASDAQ: EVGN) and Arcadia Biosciences (NASDAQ:RKDA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.

Risk and Volatility

Evogene has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Arcadia Biosciences has a beta of -5.7, suggesting that its stock price is 670% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Evogene and Arcadia Biosciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evogene 0 0 0 0 N/A
Arcadia Biosciences 0 1 0 0 2.00

Arcadia Biosciences has a consensus price target of $20.00, indicating a potential upside of 103.46%. Given Arcadia Biosciences’ higher probable upside, analysts plainly believe Arcadia Biosciences is more favorable than Evogene.

Valuation & Earnings

This table compares Evogene and Arcadia Biosciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evogene $3.38 million 22.86 -$20.83 million ($0.81) -3.70
Arcadia Biosciences $4.03 million 6.05 -$15.70 million ($6.86) -1.43

Arcadia Biosciences has higher revenue and earnings than Evogene. Evogene is trading at a lower price-to-earnings ratio than Arcadia Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evogene and Arcadia Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evogene -616.33% -27.15% -24.51%
Arcadia Biosciences -686.10% -259.46% -82.98%

Insider & Institutional Ownership

35.7% of Evogene shares are owned by institutional investors. Comparatively, 15.2% of Arcadia Biosciences shares are owned by institutional investors. 17.7% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Evogene beats Arcadia Biosciences on 7 of the 12 factors compared between the two stocks.

Evogene Company Profile

Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. It operates through two segments, Evogene and Evofuel. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants, which include microbial-based products that are applied externally to the plant for yield enhancement. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced species of the castor bean plant to serve as a source of feedstock for biofuel and other industrial uses. The company has strategic collaborations with various agricultural companies, including BASF, Bayer, DuPont, Monsanto, and Syngenta that cover 24 products in various stages of development. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaboration with Dow AgroSciences to develop and commercialize enhanced wheat quality trait. The company was founded in 2002 and is headquartered in Davis, California.

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply